Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949954 | 0.95 | F9 (0.45) | F9LMNAFFAR1FFAR4NPY2R | |
| SCHEMBL1948923 | 0.94 | F9 (0.44) | F9LMNAFFAR1FFAR4NPY2R | |
| Hydrochloric Acid SCHEMBL1947073 | 0.88 | F9 (0.48) | F9LMNAFFAR1FFAR4JAK2 | |
| SCHEMBL1948267 | 0.87 | F9 (0.36) | F9LMNAFFAR1FFAR4NPY2R | |
| SCHEMBL1438333 | 0.86 | F9 (0.43) | F9LMNAAR | |
| SCHEMBL1947208 | 0.86 | F9 (0.48) | F9JAK2JAK1RAF1BRAF | |
| Hydrochloric Acid SCHEMBL16579475 | 0.84 | F9 (0.48) | F9LMNAFFAR1FFAR4P2RY1 | |
| Hydrochloric Acid SCHEMBL1947052 | 0.83 | F9 (0.48) | F9LMNAFFAR1FFAR4P2RY1 | |
| SCHEMBL1441667 | 0.82 | F9 (0.47) | F9RAF1BRAF | |
| SCHEMBL1444821 | 0.82 | F9 (0.45) | F9AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | F9 2/4885LMNA 95/4885FFAR1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.